Geode Capital Management LLC cut its stake in Bruker Corporation (NASDAQ:BRKR – Free Report) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,072,846 shares of the medical research company’s stock after selling 12,218 shares during the period. Geode Capital Management LLC owned about 1.36% of Bruker worth $97,673,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in BRKR. Royal Bank of Canada grew its stake in Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after acquiring an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Bruker in the 1st quarter worth about $262,000. Goldman Sachs Group Inc. grew its stake in Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after acquiring an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Bruker by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after acquiring an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth grew its stake in Bruker by 115.0% in the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after acquiring an additional 6,008 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. TD Cowen upped their target price on shares of Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a research note on Thursday, May 7th. Stifel Nicolaus set a $45.00 target price on shares of Bruker in a research note on Friday, May 8th. Barclays upped their target price on shares of Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Wolfe Research initiated coverage on shares of Bruker in a report on Monday, June 1st. They set a “peer perform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $50.54.
Insider Activity at Bruker
In other Bruker news, VP Mark Munch sold 2,000 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 27.20% of the company’s stock.
Bruker Stock Down 6.0%
Shares of Bruker stock opened at $56.39 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.54. The firm’s 50-day moving average is $42.57 and its two-hundred day moving average is $43.45. The stock has a market cap of $8.58 billion, a price-to-earnings ratio of -234.96, a PEG ratio of 1.81 and a beta of 1.31.
Bruker (NASDAQ:BRKR – Get Free Report) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. During the same period in the prior year, the business earned $0.47 EPS. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.
Bruker Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 22nd. Bruker’s dividend payout ratio is presently -83.33%.
About Bruker
Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.
Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.
In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.
Featured Stories
- Five stocks we like better than Bruker
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
